IBI3034 SAD/MAD Study in Healthy Adults and Primary IgA Nephropathy

Phase 1, randomised, double-blind trial of IBI3034 in IgA nephropathy (IgAN) (3 arms), sponsored by Innovent Biologics. Primary endpoints: Incidence of adverse events and serious adverse events following a single dose at 169 days and Incidence of adverse events and serious adverse events following multiple doses at 252 days. Planned start Oct 2026; status: not yet recruiting.